CM-AT

About Curemark

Curemark is a clinical-stage biotech pioneering a novel approach to neurological disorders by targeting underlying enzyme deficiencies, particularly in protein digestion. The company's lead asset, CM-AT for Autism Spectrum Disorder, has completed pivotal studies and represents a potential first-in-class treatment. Curemark's proprietary platform, which links pancreatic enzyme function to neurotransmitter production, also supports a broader pipeline targeting ADHD, addiction, Parkinson's, and schizophrenia. As a private company, its near-term success hinges on advancing CM-AT towards regulatory approval and commercialization.

Therapeutic Areas

Other Autism Spectrum Disorder (ASD) Drugs